Evidence map›Paper›PMID 35082782›Full record

ArticleFrontiers in immunology2021

Liver Bacterial Dysbiosis With Non-Tuberculosis Mycobacteria Occurs in SIV-Infected Macaques and Persists During Antiretroviral Therapy.

Bridget S Fisher, Katherine A Fancher, Andrew T Gustin, Cole Fisher, Matthew P Wood, Michael Gale, Benjamin J Burwitz, Jeremy Smedley, Nichole R Klatt, Nina Derby and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Bridget S FisherSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.
Katherine A FancherSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.
Andrew T GustinCenter for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA, United States.
Cole FisherSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.
Matthew P WoodSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.
Michael GaleCenter for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA, United States.
Benjamin J BurwitzVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, United States.
Jeremy SmedleyOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
Nichole R KlattDepartment of Surgery, University of Minnesota, Minneapolis, MN, United States.
Nina DerbySeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.
Donald L SodoraSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.
Infectious Disease Research Institute · USUniversity of Washington · USOregon Health & Science University · USOregon National Primate Research Center · USUniversity of Minnesota · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Judith Tsui · 1988 to 2026
$104.9M
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Mediators of fatty liver disease during HIV/SIV and cART treatmentR01AI134630 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI SODORA, DONALD L · 2018 to 2022
$4.5M
Inhibition of Liver Macrophage activation in SIV infected macaquesR21AI100782 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI SODORA, DONALD L · 2013 to 2014
$541k
Mucosal Immune Dysfunction after SIV InfectionK22AI098440 · NIAID · UNIVERSITY OF WASHINGTON · PI KLATT, NICHOLE ROSE · 2013 to 2014
$270k
NIAID NIH HHS HHSN272201300010CNIAID NIH HHS HHSN272201300010INIAID NIH HHS K22 AI098440NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI134630NIAID NIH HHS R21 AI100782NIAID NIH HHS T32 AI007509NIAID NIH HHS U01 AI151698NIH HHS P51 OD010425
6 · The paper itself

Abstract

Liver disease is a significant contributor to morbidity and mortality in HIV-infected individuals, even during successful viral suppression with combination antiretroviral therapy (cART). Similar to HIV infection, SIV infection of rhesus macaques is associated with gut microbiome dysbiosis and microbial translocation that can be detected systemically in the blood. As microbes leaving the intestines must first pass through the liver

Indexed as

CoinfectionDysbiosisMycobacterium Infections, NontuberculousSimian Acquired Immunodeficiency SyndromeAnimalsAnti-Retroviral AgentsHumansLiverMacaca mulattaNontuberculous MycobacteriaSimian Immunodeficiency VirusAnti-Retroviral Agents16S rRNA geneHIV/SIVlivermicrobiomeneutrophils

Identifiers

PMID35082782
PMCPMC8784802
OpenAlexW4205970134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.